Portal de Periódicos da CAPES

TARGET OF SKIN TUMORIGENESIS: CYCLIN D1‐CDK4

1996; Wiley; Volume: 35; Issue: 9 Linguagem: Inglês

10.1111/j.1365-4362.1996.tb03681.x

1365-4632

Shinichi Inohara, Keiko Kitagawa, Yukio Kitano,

Vascular Tumors and Angiosarcomas

International Journal of DermatologyVolume 35, Issue 9 p. 609-613 TARGET OF SKIN TUMORIGENESIS: CYCLIN D1-CDK4 SHINICHI INOHARA M.D., Corresponding Author SHINICHI INOHARA M.D. Department of Dermatology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.Address for correspondence: Shinichi Inohara, M.D., Department of Dermatology, Hyogo College of Medicine, Nishinomiya, Hyogo 663, Japan.Search for more papers by this authorKEIKO KITAGAWA M.D., KEIKO KITAGAWA M.D. Department of Dermatology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.Search for more papers by this authorYUKIO KITANO M.D., YUKIO KITANO M.D. Department of Dermatology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.Search for more papers by this author SHINICHI INOHARA M.D., Corresponding Author SHINICHI INOHARA M.D. Department of Dermatology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.Address for correspondence: Shinichi Inohara, M.D., Department of Dermatology, Hyogo College of Medicine, Nishinomiya, Hyogo 663, Japan.Search for more papers by this authorKEIKO KITAGAWA M.D., KEIKO KITAGAWA M.D. Department of Dermatology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.Search for more papers by this authorYUKIO KITANO M.D., YUKIO KITANO M.D. Department of Dermatology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.Search for more papers by this author First published: September 1996 https://doi.org/10.1111/j.1365-4362.1996.tb03681.xCitations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Hunter T, Pines J. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573–582. 2 Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73: 1059–1065. 3 Zhang Y-J, Jiang W, Chen CJ, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 1993; 196: 1010–1016. 4 Jiang W, Zhang Y-J, Kahn SM, et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993; 90: 9026–9030. 5 Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812–1817. 6 Bartkova J, Lukas J, Müller H, et al. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995; 55: 949–956. 7 Schauer IE, Siriwardana S, Langan TA, et al. Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small-cell and small-cell lung cancer. Proc Natl Acad Sci USA 1994; 91: 7827–7831. 8 Jares P, Fernández PL, Campo E, et al. PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 1994; 54: 4813–4817. 9 Peters G. The D-type cyclins and their role in tumorigenesis. J Cell Sci 1994; 18: 89–96. 10 Khatib ZA, Matsushime H, Valentine M, et al. Coamplification of the cdk4 gene with MDM2 and GLI in human sarcomas. Cancer Res 1993; 53: 5535–5541. 11 Tam SW, Theodoras AM, Shay JW, et al. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with cdk4 is required for cyclin D1 function in G1 progression. Oncogene 1994; 9: 2663–2674. 12 Reifenberger G, Reifenberger J, Ichimura K, et al. Amplification of multiple genes from chromosomal region 12q 13–14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involve ment of cdk4, SAS, and MDM2. Cancer Res 1994; 54: 4299–4303. 13 He J, Allen JR, Collins VP, et al. cdk4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994; 54: 5804–5807. 14 Schmidt EE, Ichimura K, Reifenberger G, et al. cdkN2 (p16/MTS1) gene deletion or cdk4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54: 6321–6324. 15 Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/cdk4. Nature 1993; 366: 704–707. 16 Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–440. 17 Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753–756. 18 Mori T, Miura K, Aoki T, et al. Frequent somatic mutation of the MTS1/cdk41 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994; 54: 3396–3397. 19 Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nature Genet 1994; 8: 15–21. 20 Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Gene 1994; 8: 27–32. 21 Hollstein M, Sidransky D, Vogelstein B, et al. p53 Mutations in human cancers. Science 1991; 253: 49–53. 22 El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825. 23 Hunter T. Braking the cycle. Cell 1993; 75: 839–841. 24 Leach FS, Tokino T, Meltzer P, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231–2234. 25 Kao GF, Kao WH. Malignant transformation of keratinocytes by human papillomaviruses. J Cutan Pathol 1994; 21: 193–199. 26 Hall PA, Ray A, Lemoine NR, et al. p53 Immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 1991; 338: 513. 27 Michalides R, van Veelen N, Hart A, et al. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55: 975–978. 28 Bartkova J, Lukas J, Strauss M, et al. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995; 10: 775–778. 29 Inohara S, Kitano Y, Kitagawa K. Cell cycle regulators in the keratinocytes (cyclin-cdk). Exp Dermatol 1995; 4: 1–8. 30 Soini Y, Kamel D, Paakko P, et al. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. Br J Dermatol 1994; 131: 514–520. 31 Inohara S, Kitano Y. Immunohistochemical detection of cyclin D and cyclin A in human hyperproliferative epidermis. Arch Dermatol Res 1994; 286: 504–506. 32 Inohara S, Kitagawa K, Kitano Y. Expression of cyclin D1 and p53 protein in various malignant skin tumors. Dermatology 1996; 192: 94–98. 33 Yang W, Zukerberg LR, Motokura T, et al. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994; 145: 86–96. 34 Bianchi AB, Fischer SM, Robles Al, et al. Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene 1993; 8: 1127–1133. 35 Inohara S. Studies and perspectives of signal transduction in the skin. Exp Dermatol 1992; 1: 207–220. 36 Winston JT, Pledger WJ. Growth factor regulation of cyclin D1 mRNA expression through protein synthesis-dependent and -independent mechanisms. Mol Biol Cell 1993; 4: 1133–1144. 37 Filmus J, Robles Al, Shi W, et al. Induction of cyclin D1 overexpression by activated ras. Oncogene 1994; 9: 3627–3633. 38 Igaki H, Sasaki H, Kishi T, et al. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem Biophys Res Commun 1994; 203: 1090–1095. 39 Kettler AH, Rutledge M, Tschen JA, et al. Detection of human papillomavirus in nongenital Bowen's disease by in situ DNA hybridization. Arch Dermatol 1990; 126: 777–781. 40 Hawley-Nelson P, Vousden KH, Hubbert NL, et al. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8: 3905–3910. 41 Weiss J, Cavenee WK, Herbst RA, et al. Point mutations and allelic loss in the TP53 locus of cutaneous malignant melanomas. Arch Dermatol Res 1994; 286: 417–419. 42 Lübbe J, Reichel M, Burg G, et al. Absence of p53 gene mutations in cutaneous melanoma. J Invest Dermatol 1994; 102: 819–821. 43 Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855–4878. 44 Ohta M, Nagai H, Shimizu M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, cdk41, in melanoma. Cancer Res 1994; 54: 5269–5272. 45 Okamoto A, Demetrick DJ, Spillare EA, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994; 91: 11045–11049. 46 Serrano M, Gomez-Lahoz E, De Pinho RA, et al. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995; 267: 249–252. 47 Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–1245. 48 Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 1993; 362: 857–860. 49 Sreekantaiah C, Ladanyi M, Rodriguez E, et al. Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms. Am J Pathol 1994; 144: 1121–1134. 50 Keatings L, Sinclair J, Wright C, et al. c-erbB-2 Oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study. Histopathology 1990; 17: 243–247. 51 Matsushime H, Roussel MF, Ashmun RA, et al. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 1991; 65: 701–713. 52 Won K-A, Xiong Y, Beach D, et al. Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci USA 1992; 89: 9910–9914. 53 Koch KS, Lu XP, Leffert HL. Primary rat hepatocytes express cyclin D1 messenger UNA during their growth cycle and during mitogenic transitions induced by transforming growth factor-alpha. Biochem Biophys Res Commun 1994; 204: 91–97. 54 Daksis JI, Lu RY, Facchini LM, et al. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 1994; 9: 3635–3645. 55 Stainman RA, Hoffman B, Iro A, et al. Induction of p21 (WAF-1/C1P1) during differentiation. Oncogene 1994; 9: 3389–3396. 56 Jiang H, Lin J, Su Z, et al. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1 expression in the absence of p53. Oncogene 1994; 9: 3397–3406. 57 Michieli P, Chedid M, Lin D, et al. Induction of WAF1/CIP1 by a p53–independent pathway. Cancer Res 1994; 54: 3391–3395. 58 Demers GW, Foster SA, Halbert CL, et al. Growth arrest by induction of p53 in DNA-damaged keratinocytes is bypassed by human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 1994; 91: 4382–4386. 59 Slebos RJC, Lee MH, Plunkett BS, et al. p53-Dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 1994; 91: 5320–5324. Citing Literature Volume35, Issue9September 1996Pages 609-613 ReferencesRelatedInformation